IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v13y2022i1d10.1038_s41467-022-30882-8.html
   My bibliography  Save this article

Plasmodium falciparum 7G8 challenge provides conservative prediction of efficacy of PfNF54-based PfSPZ Vaccine in Africa

Author

Listed:
  • Joana C. Silva

    (University of Maryland School of Medicine
    University of Maryland School of Medicine)

  • Ankit Dwivedi

    (University of Maryland School of Medicine)

  • Kara A. Moser

    (University of Maryland School of Medicine)

  • Mahamadou S. Sissoko

    (University of Science, Techniques and Technologies of Bamako)

  • Judith E. Epstein

    (Naval Medical Research Center)

  • Sara A. Healy

    (Laboratory of Malaria Immunology and Vaccinology, NIAID, NIH)

  • Kirsten E. Lyke

    (Center for Vaccine Development and Global Health, University of Maryland School of Medicine)

  • Benjamin Mordmüller

    (University of Tübingen and German Center for Infection Research
    Centre de Recherches Médicales de Lambaréné
    Radboud University Medical Center)

  • Peter G. Kremsner

    (University of Tübingen and German Center for Infection Research
    Centre de Recherches Médicales de Lambaréné)

  • Patrick E. Duffy

    (Laboratory of Malaria Immunology and Vaccinology, NIAID, NIH)

  • Tooba Murshedkar

    (Sanaria Inc.)

  • B. Kim Lee Sim

    (Sanaria Inc.)

  • Thomas L. Richie

    (Sanaria Inc.)

  • Stephen L. Hoffman

    (Sanaria Inc.)

Abstract

Controlled human malaria infection (CHMI) has supported Plasmodium falciparum (Pf) malaria vaccine development by providing preliminary estimates of vaccine efficacy (VE). Because CHMIs generally use Pf strains similar to vaccine strains, VE against antigenically heterogeneous Pf in the field has been required to establish VE. We increased the stringency of CHMI by selecting a Brazilian isolate, Pf7G8, which is genetically distant from the West African parasite (PfNF54) in our PfSPZ vaccines. Using two regimens to identically immunize US and Malian adults, VE over 24 weeks in the field was as good as or better than VE against CHMI at 24 weeks in the US. To explain this finding, here we quantify differences in the genome, proteome, and predicted CD8 T cell epitopes of PfNF54 relative to 704 Pf isolates from Africa and Pf7G8. We show that Pf7G8 is more distant from PfNF54 than any African isolates tested. We propose VE against Pf7G8 CHMI for providing pivotal data for malaria vaccine licensure for travelers to Africa, and potentially for endemic populations, because the genetic distance of Pf7G8 from the Pf vaccine strain makes it a stringent surrogate for Pf parasites in Africa.

Suggested Citation

  • Joana C. Silva & Ankit Dwivedi & Kara A. Moser & Mahamadou S. Sissoko & Judith E. Epstein & Sara A. Healy & Kirsten E. Lyke & Benjamin Mordmüller & Peter G. Kremsner & Patrick E. Duffy & Tooba Murshed, 2022. "Plasmodium falciparum 7G8 challenge provides conservative prediction of efficacy of PfNF54-based PfSPZ Vaccine in Africa," Nature Communications, Nature, vol. 13(1), pages 1-9, December.
    • Handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-30882-8
    DOI: 10.1038/s41467-022-30882-8
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-022-30882-8
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-022-30882-8?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Benjamin Mordmüller & Güzin Surat & Heimo Lagler & Sumana Chakravarty & Andrew S. Ishizuka & Albert Lalremruata & Markus Gmeiner & Joseph J. Campo & Meral Esen & Adam J. Ruben & Jana Held & Carlos Lam, 2017. "Sterile protection against human malaria by chemoattenuated PfSPZ vaccine," Nature, Nature, vol. 542(7642), pages 445-449, February.
    2. Zita Sulyok & Rolf Fendel & Bianca Eder & Freia-Raphaella Lorenz & Natasha KC & Matthias Karnahl & Albert Lalremruata & The T. Nguyen & Jana Held & Folashade Almeine Cyntiche Adjadi & Torsten Klockenb, 2021. "Heterologous protection against malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial," Nature Communications, Nature, vol. 12(1), pages 1-10, December.
    3. Agnes Mwakingwe-Omari & Sara A. Healy & Jacquelyn Lane & David M. Cook & Sahand Kalhori & Charles Wyatt & Aarti Kolluri & Omely Marte-Salcedo & Alemush Imeru & Martha Nason & Lei K. Ding & Hope Decede, 2021. "Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity," Nature, Nature, vol. 595(7866), pages 289-294, July.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Prasanna Jagannathan & Abel Kakuru, 2022. "Malaria in 2022: Increasing challenges, cautious optimism," Nature Communications, Nature, vol. 13(1), pages 1-3, December.
    2. Hardik Patel & Nana K. Minkah & Sudhir Kumar & Gigliola Zanghi & Antonino Schepis & Debashree Goswami & Janna Armstrong & Biley A. Abatiyow & Will Betz & Laura Reynolds & Nelly Camargo & Amina A. Shei, 2024. "Malaria blood stage infection suppresses liver stage infection via host-induced interferons but not hepcidin," Nature Communications, Nature, vol. 15(1), pages 1-13, December.
    3. Raquel Furtado & Mahinder Paul & Jinghang Zhang & Joowhan Sung & Paul Karell & Ryung S. Kim & Sophie Caillat-Zucman & Li Liang & Philip Felgner & Andy Bauleni & Syze Gama & Andrea Buchwald & Terrie Ta, 2023. "Cytolytic circumsporozoite-specific memory CD4+ T cell clones are expanded during Plasmodium falciparum infection," Nature Communications, Nature, vol. 14(1), pages 1-20, December.
    4. Patricia Ferrer & Andrea A. Berry & Allison N. Bucsan & Surendra K. Prajapati & Karthik Krishnan & Michelle C. Barbeau & David M. Rickert & Sandra Mendoza Guerrero & Miho Usui & Yonas Abebe & Asha Pat, 2024. "Repeat controlled human Plasmodium falciparum infections delay bloodstream patency and reduce symptoms," Nature Communications, Nature, vol. 15(1), pages 1-13, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-30882-8. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.